Roche's Tecentriq Notches Approval For First-Line NSCLC Monotherapy

The next big thing lined up for Roche in lung cancer is its dual checkpoint approach of its novel TIGIT inhibitor tiragolumab plus its stalwart PD-L1 inhibitor Tecentriq. But the 18 May approval of Tecentriq monotherapy for first-line non-small cell lung cancer is an important step in the company’s strategy of building its way into immuno-oncology dominance by thorough execution.